{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T21:34:33Z","timestamp":1787693673672,"version":"build-2784847793"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.jneuroim.2008.04.039","type":"journal-article","created":{"date-parts":[[2008,7,24]],"date-time":"2008-07-24T04:57:28Z","timestamp":1216875448000},"page":"90-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"special_numbering":"C","title":["Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients"],"prefix":"10.1016","volume":"201-202","author":[{"given":"Isabel","family":"Illa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Diaz-Manera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Rojas-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Pradas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Blesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candido","family":"Juarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2008.04.039_bib1","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/jnnp.2006.093567","article-title":"Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis","volume":"78","author":"Baek","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2008.04.039_bib2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-MuSK antibodies: correlation with myasthenia gravis severity","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.04.039_bib3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11910-007-0072-9","article-title":"Progressive multifocal leukoencephalopathy","volume":"7","author":"Berger","year":"2007","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/ncpneuro0033","article-title":"Autoimmune channelopathies","volume":"1","author":"Buckley","year":"2005","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1191\/0961203305lu2138oa","article-title":"Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases","volume":"14","author":"Chambers","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.jneuroim.2008.04.039_bib6","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib7","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/01.wnl.0000254620.45529.97","article-title":"Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis","volume":"68","author":"Deymeer","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.04.039_bib8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/ncpneuro0526","article-title":"Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome","volume":"3","author":"Diaz-Manera","year":"2007","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib9","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2008.04.039_bib10","first-page":"1","article-title":"Intravenous immunoglobulin for myasthenia gravis","volume":"1","author":"Gajdos","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib11","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ajh.20169","article-title":"Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma","volume":"77","author":"Gajra","year":"2004","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib12","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.20479","article-title":"Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab","volume":"33","author":"Hain","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2008.04.039_bib13","first-page":"1","article-title":"Immunosuppressive agents for myasthenia gravis","volume":"4","author":"Hart","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jnnp.2007.134130","article-title":"When the patient fails to respond to treatment: myasthenia gravis","volume":"7","author":"Hilton-Jones","year":"2007","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib16","doi-asserted-by":"crossref","first-page":"I14","DOI":"10.1007\/s00415-005-1104-5","article-title":"IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status","volume":"252 Suppl 1","author":"Illa","year":"2005","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1157\/13076937","article-title":"\u201cSeronegative\u201d myasthenia gravis and antiMuSK positive antibodies: description of Spanish series","volume":"125","author":"Illa","year":"2005","journal-title":"Med. Clin. (Barc.)"},{"key":"10.1016\/j.jneuroim.2008.04.039_bib18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.04.039_bib19","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/mus.20030","article-title":"Clinical evaluation and management of myasthenia gravis","volume":"29","author":"Keesey","year":"2004","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2008.04.039_bib20","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.04.039_bib21","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-2003-41135","article-title":"Therapy in myasthenia gravis and Lambert\u2013Eaton myasthenic syndrome","volume":"23","author":"Newsom-Davis","year":"2003","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib23","first-page":"5","article-title":"The emerging diversity of neuromuscular junction disorders","volume":"26","author":"Newsom-Davis","year":"2007","journal-title":"Acta Myol."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib24","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib25","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1212\/01.WNL.0000098887.24618.A0","article-title":"Treatment of autoimmune myasthenia gravis","volume":"61","author":"Richman","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.04.039_bib26","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","article-title":"Clinical aspects of MuSK antibody positive seronegative MG","volume":"60","author":"Sanders","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.04.039_bib27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1055\/s-2004-829586","article-title":"Management of myasthenia gravis","volume":"24","author":"Saperstein","year":"2004","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib28","first-page":"1","article-title":"Corticosteroids for myasthenia gravis","volume":"2","author":"Schneider-Gold","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib29","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/01.LAB.0000028144.48023.9B","article-title":"Anti-p110 autoantibodies identify a subtype of \u201cseronegative\u201d myasthenia gravis with prominent oculobulbar involvement","volume":"82","author":"Scuderi","year":"2002","journal-title":"Lab. Invest."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.coph.2005.01.010","article-title":"Myasthenia gravis: emerging new therapy options","volume":"5","author":"Sieb","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib31","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1468-1331.2006.01476.x","article-title":"Guidelines for the treatment of autoimmune neuromuscular transmission disorders","volume":"13","author":"Skeie","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib32","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.clinph.2005.06.003","article-title":"MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns","volume":"116","author":"Stickler","year":"2005","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ncprheum0424","article-title":"Drug insight: the mechanism of action of rituximab in autoimmune disease\u2014the immune complex decoy hypothesis","volume":"3","author":"Taylor","year":"2007","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib34","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s00415-006-0442-2","article-title":"Rituximab in refractory MuSK antibody myasthenia gravis","volume":"254","author":"Thakre","year":"2007","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib35","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/rheumatology\/keh443","article-title":"Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab","volume":"44","author":"Tokunaga","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jneuroim.2008.04.039_bib36","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/01.wco.0000180660.57801.3f","article-title":"Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis","volume":"18","author":"Vincent","year":"2005","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib37","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1474-4422(03)00306-5","article-title":"Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets","volume":"2","author":"Vincent","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib38","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1067\/S0022-3476(03)00300-7","article-title":"Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report","volume":"143","author":"Wylam","year":"2003","journal-title":"J. Pediatr."},{"key":"10.1016\/j.jneuroim.2008.04.039_bib39","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.55.7.1062-a","article-title":"Rituximab for myasthenia gravis developing after bone marrow transplant","volume":"55","author":"Zaja","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2008.04.039_bib40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mus.20069","article-title":"Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients","volume":"30","author":"Zhou","year":"2004","journal-title":"Muscle Nerve"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572808002129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572808002129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:10:33Z","timestamp":1759047033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572808002129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":40,"alternative-id":["S0165572808002129"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2008.04.039","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2008.04.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}